iRhythm Technologies, Inc. (IRTC)

In the past six months, iRhythm Technologies' stock has experienced several notable events. The company reported its Q2 2025 earnings, beating both EPS and revenue estimates, with revenue increasing year-over-year. This contributed to a significant increase in the stock price. The company is scheduled to release its Q3 2025 financial results on October 30, 2025. Analysts have generally maintained favorable ratings and raised their outlooks for iRhythm. There has been some insider selling. iRhythm also participated in several major healthcare conferences in September 2025. The FDA granted clearance for the first of two 510(k) submissions for the Zio AT system, although there was a voluntary delay in regulatory submissions for the next-generation Zio MCT system until Q3 2025. The company also raised its full-year revenue guidance.

While specific detailed information on the demand seasonality for iRhythm Technologies' products and services is limited, historical stock data suggests that October has historically favored a long bias for IRTC. The company's Q1 2024 earnings call indicated strong market demand for its Zio products and services, with momentum continuing into Q2 2024.

iRhythm Technologies, Inc. is a digital healthcare company specializing in solutions for detecting and monitoring cardiac arrhythmias. Their primary product is the Zio platform, which includes the Zio XT for continuous monitoring and the Zio AT for near real-time monitoring. The company also develops the Zio Watch in conjunction with its clinically integrated ZEUS System. iRhythm integrates data analytics and AI into its services, using algorithms to analyze data and provide insights. They also offer end-to-end clinical services, including data processing, report generation, and physician support.

iRhythm Technologies primarily offers its Zio service in the United States, reaching physicians, hospitals, and clinics through a direct sales organization. The company has also demonstrated significant international expansion, with notable growth in the UK and entry into four new European countries. A commercial launch of the Zio monitor in Japan is anticipated in the first half of 2025. The company's deep-learned algorithm is available in the United States, European Union, Switzerland, United Kingdom, and Japan.

In the past year, iRhythm Technologies' brand reputation has been influenced by regulatory and clinical developments. The company received an FDA warning letter concerning changes made to its Zio AT System, initially causing a dip in stock price, but the FDA later granted clearance for iRhythm's retrospective 510(K) submission for Zio AT, which positively impacted the stock. The company has since emphasized its commitment to quality and regulatory compliance. iRhythm's reputation is bolstered by positive analyst sentiment and upgrades. The company has also achieved a milestone of over 1 million patients registered for the Zio monitor. The ongoing Pediatric Adhesion and New Dermal Approach Study (PANDA) is evaluating the feasibility of using the Zio monitor in children. A high level of physician satisfaction is also reported.

iRhythm Technologies has a significant level of institutional ownership. Major institutional owners include Vanguard Group Inc., Sands Capital Management LLC, and BlackRock Inc. Insider ownership ranges from about 1.10% to 30.97%. Synergy Life Science Partners L P is noted as the largest individual shareholder, while other significant insider owners include Holdings A. Novo and New Leaf Ventures II LP. Frank Sands is also identified as owning a substantial number of shares.